EUVIMEDEUVIMED entdecken
Open Access

Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP ‐1 Receptor Agonists

Solomon Chih-Cheng Chen iD, Tso-Jen Wang, Chu-Kuang Chou iD, Chun Lee

Diabetes, Obesity and Metabolism · 2026-10 · 28 (10) · 8895-8904

DOI: 10.1111/dom.71088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.07.2026. Verfasst von Solomon Chih-Cheng Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan. Hauptthemen laut MEDLINE: Tirzepatide, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin‐based therapies for type 2 diabetes mellitus (T2DM) and obesity. However, whether risks differ across successive generations of incretin‐based therapies remains uncertain. Materials and Methods This retrospective cohort study used the TriNetX Global Federated Network (> 192 million patients). Adults with T2DM, obesity, or both initiating tirzepatide, semaglutide, or other glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) between July 2022 and June 2025 were identified using a new‐user design with a 12‐month washout. Propensity score matching balanced demographic, clinical, and metabolic variables. Two comparisons were conducted: tirzepatide versus semaglutide and semaglutide versus other GLP‐1 RAs. Follow‐up included Year 1 (day 31–365) and Year 2 landmark analysis (day 366–730). Hazard ratios (HRs) for incident depression, anxiety, and suicidal ideation were estimated using Cox models.

Results

After matching, 85 546 pairs were included for tirzepatide versus semaglutide and 80 115 pairs for semaglutide versus other GLP‐1 RAs. Tirzepatide and semaglutide showed similar risks for the composite psychiatric outcome (Year 1 HR 0.984 [95% CI 0.950–1.019]; Year 2 HR 1.002 [0.960–1.046]); a nominally higher anxiety hazard was observed with tirzepatide during Year 2 (HR 1.052 [1.001–1.106]), which should be interpreted cautiously given multiple comparisons. Compared with other GLP‐1 RAs, semaglutide was associated with lower risks of depression (HR 0.811 [0.770–0.855]), anxiety (HR 0.915 [0.871–0.961]), suicidal ideation (HR 0.488 [0.339–0.702]), and the composite psychiatric outcome (HR 0.866 [0.832–0.901]) during Year 1.

Conclusions

In real‐world practice, tirzepatide and semaglutide demonstrated comparable neuropsychiatric risk profiles over 2 years. Semaglutide was associated with lower psychiatric event rates compared with earlier‐generation GLP‐1 receptor agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesDiabetes Mellitus, Type 2Hypoglycemic AgentsObesityHumansSemaglutideFemaleMaleRetrospective StudiesMiddle AgedDepressionSuicidal IdeationAnxietyAdultAgedIncretins

Stichwörter der Autor:innen

cohort studiescomparative effectiveness researchdepressive disorderglucagon‐like peptide‐1 receptor agonistspostmarketing surveillancereal‐world evidencesuicidal ideation

Substanzen

TirzepatideSemaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsIncretins

Autor:innen und Institutionen

  • Department of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.
  • Department of Pediatrics, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi City, Taiwan.
  • Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.
  • Obesity Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.
  • Clinical Data Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan.

ORCID-Profile: Solomon Chih-Cheng Chen, Chu-Kuang Chou

Zitieren

APA

Chen, S. C., Wang, T. J., Chou, C. K., & Lee, C. (2026). Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP ‐1 Receptor Agonists. Diabetes, Obesity and Metabolism, 28(10), 8895-8904. https://doi.org/10.1111/dom.71088

Vancouver

Chen SC, Wang TJ, Chou CK, Lee C. Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP ‐1 Receptor Agonists. Diabetes, Obesity and Metabolism. 2026;28(10):8895-8904. doi:10.1111/dom.71088

BibTeX
@article{Chen2026,
  author = {Chen, Solomon Chih-Cheng and Wang, Tso-Jen and Chou, Chu-Kuang and Lee, Chun},
  title = {Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP ‐1 Receptor Agonists},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {10},
  pages = {8895--8904},
  doi = {10.1111/dom.71088}
}
Kostenlos starten →